APPLICATION
ANDA204329
TYPE
ANDA
ORIGINAL APPROVAL
2021-06-16
LATEST ACTION
2026-02-03
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
IBANDRONATE SODIUMDiscontinued
IBANDRONATE SODIUM EQ 3MG BASE/3ML · INJECTABLE · INTRAVENOUS
Approval history
2026-02-03Labeling · Supplement 2 · standardAP
2021-06-16UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.